Month: March 2024
NEW YORK, NY, March 27, 2024 (GLOBE NEWSWIRE) — via NewMediaWire — Applied UV, Inc. (NASDAQ: AUVI; AUVIP) (“Applied UV” or the “Company”), a leader in smart building technology solutions, today announced that it has entered into definitive agreements with institutional investors for the purchase and sale of common stock of the Company (“Common Stock”) and pre-funded warrants (“Pre-Funded Warrants”) in a registered direct offering. In a concurrent private placement, the Company also agreed to sell to the same investors, common warrants (“Common Warrants”). Aggregate gross proceeds to the Company from both transactions are expected to be approximately $2.76 million, the maximum availability under the effective shelf registration statement.
The transactions consist of (i) the public sale of an aggregate of 1,726,875 shares of...
Soitec confirms guidance for FY’24 and publishes its outlook for FY’25
Written by Customer Service on . Posted in Public Companies.
Soitec confirms guidance for FY’24 and publishes its outlook for FY’25
Bernin (Grenoble), France, March 27th, 2024 – Soitec (Euronext Paris), a world leader in designing and manufacturing innovative semiconductor materials, today confirms its guidance for the fiscal year 2024 (ending on March 31st, 2024) and provides some preliminary indications about its prospects for the fiscal year 2025 (ending on March 31st, 2025).
FY’24 guidance
Soitec confirms that it expects revenue for FY’24 to decline by around 10% at constant exchange rates and perimeter and an EBITDA1 margin2 for FY’24 of around 34%, in line with the guidance given on February 7th, 2024. FY’24 results will be published on May 22nd, 2024.
FY’25 outlook
Looking ahead, Soitec continues to anticipate significant growth in its three end-markets, where it is strengthening its...
Changes to the Soitec Board of Directors
Written by Customer Service on . Posted in Public Companies.
Changes to the Soitec Board of Directors
Bernin (Grenoble), France – 27 March 2024 – At its meeting today, the Soitec Board of Directors took note of Eric Meurice’s decision not to seek renewal of his mandate as Director at the next Annual General Meeting of shareholders on 23 July 2024. At that date, Eric Meurice will step down as a Director and as Chairman of the Board. He will take on the role of strategic advisory to the Chief Executive Officer for a period of one year.
All members of the Board expressed their gratitude to Eric Meurice for his unfailing commitment to Soitec over the past six years and for his major contribution to the work of the Board, which has enabled Soitec to create value for all its stakeholders. Eric Meurice will continue in office until 23 July 2024 and will ensure a smooth handover to his successor....
Vranken-Pommery Monopole – ANNUAL RESULTS 2023 – Operating income up 12.7% to €39 million
Written by Customer Service on . Posted in Earnings Releases And Operating Results.
ANNUAL RESULTS 2023Operating income up 12.7% to €39 millionCONSOLIDATED TURNOVER
CURRENT OPERATING INCOME
EQUITY
NET FINANCIAL DEBT (excluding IFRS 16)
€ 338 million
€ 39 million
€ 420 million
€ 635 million
+1,2%
+12,7%
+2,5%
+1,4%
(vs 2022)
+3,9 €M
+4,4 €M
+10,1 €M
+9 €M
Reims, March 27, 2024
The Board of Directors of Vranken-Pommery Monopole met on March 27, 2024 under the chairmanship of Mr. Paul-François Vranken, and in the presence of the Statutory Auditors, to approve the Group’s financial statements for the year 2023.
ResultsConsolidated data in €M
31/12/2023...
Tarkett- AVAILABILITY OF THE 2023 UNIVERSAL REGISTRATION DOCUMENT
Written by Customer Service on . Posted in Public Companies.
AVAILABILITY OF THE 2023 UNIVERSAL REGISTRATION DOCUMENT
Paris, March 27, 2024 — Tarkett informs that it has filed its 2023 Universal Registration Document with the Autorité des Marchés Financiers (AMF) on March 27, 2024.
The 2023 Universal Registration Document, which includes the 2023 Annual Financial Report, includes in particular:the Management Board report;
the Supervisory Board Report on Corporate Governance;
the Extra-Financial Performance Declaration;
the Statutory Auditors reports and the information related to their fees;
the share buyback program description; and
the agenda and draft resolutions of the Combined Shareholder’s Meeting to be held on April 26, 2024.This Document is made available to the public, free of charge under the conditions provided by applicable regulations and may be consulted on the “Investors” page...
Corporate Governance Report 2023
Written by Customer Service on . Posted in Public Companies.
Corporate Governance Report 2023AttachmentRGSBCP2023EN
HighCo: 2023 annual earnings
Written by Customer Service on . Posted in Earnings Releases And Operating Results.
Aix-en-Provence, 27 March 2024 (6 p.m.)
HIGHCO: GOOD FINANCIAL RESULTS IN 2023 (22.1% OPERATING MARGIN AND EPS OF €0.55) TO TACKLE A MORE CHALLENGING YEAR IN 2024; PROPOSED DIVIDEND OF €0.20 PER SHARE
Business decline in 20232023 gross profit of €74.35 m, down 2.7% LFL1.
Digital businesses holding up well (up 1.2% LFL) and strong decline in offline businesses (down 10.6% LFL).
Drop in business in France (down 3% LFL) and less significant decline in International business (down 0.6% LFL), with Belgium holding up well.Sharp rise in profitability and in EPSHeadline PBIT2 of €16.41 m, up 4.2%.
Operating margin2 of 22.1%, with a sharp increase of 150 basis points.
Recurring operating income of €15.85 m, up 8%.
Adjusted attributable net income3 of €10.9 m, with a sharp rise of 20.9%.
Adjusted earnings per share (EPS)3 of €0.55, for a...
Indegene acquires Trilogy Writing & Consulting GmbH, a medical writing consultancy
Written by Customer Service on . Posted in Mergers And Acquisitions.
PRINCETON, N.J. and FRANKFURT, Germany, March 27, 2024 (GLOBE NEWSWIRE) — Indegene, a digital-first, life sciences commercialization company, announced the acquisition of Trilogy Writing & Consulting GmbH (Trilogy), a global provider of specialty medical writing capabilities across clinical, regulatory, safety and medical content to life sciences companies. The acquisition by Indegene Ireland, a subsidiary of Indegene Limited, augments Indegene’s depth of clinical and regulatory writing expertise for market authorization applications globally.
Trilogy Writing & Consulting is a Germany, UK, and US-based, medical writing consultancy with know-how in the development and delivery of clinical, regulatory, safety, and medical content. It applies its expertise and unique approaches to deliver quality medical writing output....
ARGAN delivered a 4,600 sq.m, Aut0nom®-labelled distribution centre to DSV in Normandie
Written by Customer Service on . Posted in Public Companies.
Press release – Neuilly-sur-Seine, Wednesday, March 27, 2024 – 5.45 pm
ARGAN delivered a 4,600 sq.m, Aut0nom® -labelled distribution centre to DSV in Normandie
Photo credit: Argan
After works that lasted for 10 months, DSV Road teams are now operating on the new distribution platform located in Eslettes (76), near Rouen. This 4,600 sq.m building, which was developed by ARGAN, is Aut0nom®-labelled, i.e. an “in-use Net Carbon Zero warehouse”.
DSV is operating this platform through its DSV Road division, as part of a nine-year fixed-term lease. This is the second time that DSV and ARGAN – which already owns the Gennevilliers buildings where the DSV French headquarters are located – work together. DSV is a front-running international company, which delivers transportation and logistics services.
Aut0nom®, an in-use Carbon Zero site
A particular...
Transgene appoints Lucie Larguier as Chief Financial Officer and Christelle Schwoerer as Chief Human Resources Officer
Written by Customer Service on . Posted in Public Companies.
Strasbourg, France, March 27, 2024, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, is pleased to announce the appointment of Lucie Larguier as Chief Financial Officer (CFO), effective immediately. Formerly VP, Corporate Communication and Investor Relations at Transgene, in her new role as CFO, Lucie Larguier will be responsible for all aspects of the Company’s financial strategy, management and operations to ensure efficient delivery of Transgene’s innovative immunotherapy pipeline. Lucie succeeds Arnaud Dubarry who has stepped down to pursue other opportunities.
Already a member of the executive management committee, Lucie Larguier brings a comprehensive, cross-functional view of the Company’s operations and finances as well as a deep...